In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice.

Studies with tracking of single nanoparticles are providing new insights into the interactions and processes involved in the transport of drug carriers in living mice. Here, we report the tracking of a single particle quantum dot (Qdot) conjugated with tumor-targeting antibody in tumors of living mice using a dorsal skinfold chamber and a high-speed confocal microscope with a high-sensitivity camera. Qdot labeled with the monoclonal anti-HER2 antibody was injected into mice with HER2-overexpressing breast cancer to analyze the molecular processes of its mechanistic delivery to the tumor. Movement of single complexes of the Qdot-antibody could be clearly observed at 30 frames/s inside the tumor through a dorsal skinfold chamber. We successfully identified six processes of delivery: initially in the circulation within a blood vessel, during extravasation, in the extracelullar region, binding to HER2 on the cell membrane, moving from the cell membrane to the perinuclear region, and in the perinuclear region. The six processes were quantitatively analyzed to understand the rate-limiting constraints on Qdot-antibody delivery. The movement of the complexes at each stage was "stop-and-go." The image analysis of the delivery processes of single particles in vivo provides valuable information on antibody-conjugated therapeutic nanoparticles, which will be useful in increasing therapeutic efficacy.

[1]  A. Santoro,et al.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  C. Benz,et al.  Emerging antibody-based HER2 (ErbB-2/neu) therapeutics. , 2000, Breast disease.

[3]  K. Fujimoto-Ouchi,et al.  Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5′-dFUrd in human breast cancer models , 2002, Cancer Chemotherapy and Pharmacology.

[4]  Paul R. Selvin,et al.  Myosin V Walks Hand-Over-Hand: Single Fluorophore Imaging with 1.5-nm Localization , 2003, Science.

[5]  Philippe Rostaing,et al.  Diffusion Dynamics of Glycine Receptors Revealed by Single-Quantum Dot Tracking , 2003, Science.

[6]  H. Higuchi,et al.  Motility of myosin V regulated by the dissociation of single calmodulin , 2005, Nature Structural &Molecular Biology.

[7]  M. Kurosumi,et al.  Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6 , 1999, British Journal of Cancer.

[8]  H. Higuchi,et al.  A mutant of the motor protein kinesin that moves in both directions on microtubules , 2000, Nature.

[9]  Vladimir P. Torchilin,et al.  Immunomicelles: Targeted pharmaceutical carriers for poorly soluble drugs , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[10]  A. Kamal,et al.  Connecting vesicle transport to the cytoskeleton. , 2000, Current opinion in cell biology.

[11]  M. Bruchez,et al.  Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots , 2003, Nature Biotechnology.

[12]  S. Lyons Advances in imaging mouse tumour models in vivo , 2005, The Journal of pathology.

[13]  R. Braun,et al.  Hemodynamic parameters in blood vessels in choroidal melanoma xenografts and rat choroid. , 2002, Investigative ophthalmology & visual science.

[14]  Donal J. Denvir,et al.  Optimization of spinning disk confocal microscopy: synchronization with the ultra-sensitive EMCCD , 2004, SPIE BiOS.

[15]  C. A. Carraway,et al.  Association of the Ras to Mitogen-activated Protein Kinase Signal Transduction Pathway with Microfilaments , 1999, The Journal of Biological Chemistry.

[16]  Hiroto Tanaka,et al.  Simultaneous Observation of Individual ATPase and Mechanical Events by a Single Myosin Molecule during Interaction with Actin , 1998, Cell.

[17]  E. Balcerczak,et al.  Uptake of radiolabelled herceptin by experimental mammary adenocarcinoma. , 2003, Nuclear medicine review. Central & Eastern Europe.

[18]  C. Mamot,et al.  Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. , 2005, Cancer research.

[19]  J. Drevs,et al.  Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study , 2004, Cancer Chemotherapy and Pharmacology.

[20]  T. Hasson,et al.  Uncoated endocytic vesicles require the unconventional myosin, Myo6, for rapid transport through actin barriers. , 2004, Molecular biology of the cell.

[21]  J. Luzio,et al.  Myosin VI isoform localized to clathrin‐coated vesicles with a role in clathrin‐mediated endocytosis , 2001, The EMBO journal.

[22]  Y. Nakanishi,et al.  Antitumor effect of MCC‐465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts , 2004, Cancer science.

[23]  H. Higuchi,et al.  Single-molecule imaging of cooperative assembly of gamma-hemolysin on erythrocyte membranes. , 2003, The EMBO journal.

[24]  U. Nielsen,et al.  Tumor targeting using anti-her2 immunoliposomes. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[25]  S. Nie,et al.  In vivo cancer targeting and imaging with semiconductor quantum dots , 2004, Nature Biotechnology.

[26]  R. Jain,et al.  Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. , 1992, Cancer research.

[27]  J. Post,et al.  Quantum dot ligands provide new insights into erbB/HER receptor–mediated signal transduction , 2004, Nature Biotechnology.

[28]  D. Scheinberg,et al.  Alpha-Particle Emitting Atomic Generator (Actinium-225)-Labeled Trastuzumab (Herceptin) Targeting of Breast Cancer Spheroids , 2004, Clinical Cancer Research.

[29]  D. Balding,et al.  HLA Sequence Polymorphism and the Origin of Humans , 2006 .